Compare Bristol-Myers Squibb Co (BMY) vs Uranium Energy Corp (UEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Uranium Energy Corp — how do they compare? Bristol-Myers Squibb Co trades at $63.67 (market cap $129.94B), while Uranium Energy Corp trades at $11.39 (market cap $5.67B). The key difference: Bristol-Myers Squibb Co is far larger — about 22.9× Uranium Energy Corp's market cap, and Bristol-Myers Squibb Co pays a 3.96% dividend while Uranium Energy Corp pays none. Which is the better fit depends on your goals.
| BMY | UEC | |
|---|---|---|
Market Cap | $129.94B | $5.67B |
Sector | Health | Energy |
52-Week High | $65.89 | $20.14 |
52-Week Low | $42.60 | $9.04 |
Enterprise Value | $163.92B | $5.18B |
Dividend Yield | 3.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $63.88, down 1.48% on the day, with strong technical momentum indicated by bullish moving averages and ADX signals. The company demonstrates robust fundamentals with a 14.01 P/E ratio, 18.87% net income margin, and consistent earnings beats in recent quarters. Recent developments include a $2.3 billion manufacturing investment in Houston and strategic AI collaboration with Schrödinger.
BMY presents a compelling investment case with attractive valuation metrics and strong profitability, though investors face risks from patent expirations and debt levels. Analyst consensus suggests 7% upside to the $68.56 price target, with the stock offering dividend income alongside growth potential from pipeline developments and potential M&A activity.
UEC trades at $11.36, down 0.18% on the day, with a bullish technical signal driven by moving averages despite a neutral oscillator reading. The company reported a net loss of $87.66 million in 2025, with revenue of $66.84 million, and faces significant profitability challenges with a negative net income margin of -513.24%. Recent news highlights insider selling and optimistic long-term uranium market forecasts.
Outlook hinges on uranium price recovery and production ramp-up, but risks include persistent losses, high valuation multiples, and execution delays. Analyst consensus is strongly bullish with 87.5% buy ratings, though fundamentals warrant caution due to cash burn and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Uranium Energy Corp
Uranium Energy Corp is a leading American uranium mining and exploration company, currently holding the largest resource base and licensed production capacity in the United States. Utilizing low-cost, environmentally friendly In-Situ Recovery (ISR) mining, UEC is a central player in the domestic nuclear fuel supply chain, transitioning from a resource holder to an active producer and refiner to meet the accelerating demand for carbon-free energy.
Read more on UEC →
